Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Initial Therapy for Tuberculosis in the Era of Multidrug Resistance -- Recommendations of the Advisory Council for the Elimination of Tuberculosis

Summary

These recommendations update previous CDC/American Thoracic Society (ATS) recommendations for the treatment of tuberculosis (TB) among adults and children (1). The most notable changes are in response to the increasing prevalence of drug-resistant TB in the United States. These recommendations include the need for a) in vitro drug susceptibility testing of Mycobacterium tuberculosis isolates from all patients and reporting of these results to the health department, b) initial four-drug regimens for the treatment of TB, and c) initial directly observed therapy for persons with TB. Adherence to these recommendations will help prevent the occurrence of more cases of drug-resistant TB, reduce the occurrence of treatment failure, and reduce the transmission of TB in the United States.

INTRODUCTION

The number of tuberculosis (TB) cases reported in the United States has declined from more than 84,000 cases in 1953 to 22,255 cases in 1984. However, since 1984 dramatic changes in TB morbidity trends have occurred, and these changes jeopardize the control of TB. From 1985 through 1991, reported TB cases increased 18% -- representing approximately 39,000 more cases than expected had the previous downward trend continued (CDC, unpublished data). The excess number of cases is due to many factors, including the human immunodeficiency virus (HIV) epidemic, a deterioration in the health-care infrastructure, and increases in the number of cases among foreign-born persons.

The recent emergence of drug-resistant TB also has become a serious concern. For example, in New York City in 1991, 33% of TB cases were resistant to at least one drug, and 19% were resistant to both isoniazid (INH) and rifampin (RIF) (2) -- the two most effective drugs available for treating TB. Resistance to both INH and RIF substantially increases the cost and duration of treatment, while decreasing the efficacy.

Based on surveys of all TB cases reported to CDC during the first quarter of 1991, cases of TB resistant to one or more drugs were reported from all 10 Health and Human Services/Public Health Service regions of the United States. Moreover, during the period 1982-1986, 0.5% of new TB cases were resistant to both INH and RIF, whereas preliminary analysis of data for the first quarter of 1991 suggests that this proportion was about 3%. Among recurrent cases, 3% were resistant to both drugs during the period 1982-1986, compared with 6.9% in 1991.

Outbreaks of multidrug-resistant TB (MDR-TB) -- resistant to both INH and RIF, as well as to other drugs -- have occurred in a variety of institutional settings. From 1990 through 1992, CDC has investigated nine outbreaks of MDR-TB in hospitals and prison facilities in Florida and New York (3-5). These outbreaks have been characterized by a high prevalence of HIV infection among the outbreak cases, range 20%-100%; a high mortality rate among patients with MDR-TB, range 72%-89%; a short median interval between TB diagnosis and death, range 4-16 weeks; and transmission of MDR-TB to health-care and correctional facility workers, at least 17 of whom have developed active MDR-TB.

Drug-resistant tubercle bacilli are transmitted in the same manner as drug-susceptible organisms. A study comparing infection rates among contacts of TB patients suggested that the likelihood of transmission was similar for both drug-resistant and drug-susceptible organisms (6). In institutional TB outbreaks investigated from 1991 to 1992, tuberculin skin-test conversions among health-care workers were more likely to be associated with exposure to patients with drug-resistant organisms than to patients with drug-susceptible organisms (3) -- probably reflecting the persistent infectiousness of patients with unrecognized drug-resistant TB who were not on effective therapy.

Mycobacterium tuberculosis becomes drug resistant through random, spontaneous genetic mutation. The proportion of naturally occurring resistance has been established for several of the primary anti-TB drugs: RIF, 1/108; INH and streptomycin (SM), 1/106; and ethambutol, (EMB) 1/104. Assuming that the mutations are independent, the likelihood of an organism spontaneously developing resistance to more than one drug is the product of probabilities; for example, the probability of INH and RIF resistance occurring in the same organism is 1/108 times 1/106 (1/1014). Because the total number of bacilli in an infected person, even with advanced cavitary disease, does not approach this number (1014), spontaneous evolution of MDR tubercle bacilli occurs infrequently.

TREATMENT

Because administration of a single drug often leads to the development of a bacterial population resistant to that drug, effective regimens for the treatment of TB must contain multiple drugs to which the organisms are susceptible. When two or more drugs are used simultaneously, each helps prevent the emergence of tubercle bacilli resistant to the others. However, when the in vitro susceptibility of a patient's isolate is not known -- which is generally the case at the beginning of therapy -- selecting two agents to which the patient's isolate is likely to be susceptible can be difficult. Improper selection of drugs for the treatment of drug-resistant TB (i.e., providing only one drug to which most organisms are susceptible) may subsequently result in the development of additional drug-resistant organisms.

A four-drug regimen with INH, RIF, pyrazinamide (PZA), and SM or EMB is preferred for the initial, empiric treatment of TB (Tables 1,2). When adherence with the regimen is assured, such as with directly observed therapy (DOT), the four-drug regimen is highly effective even for INH-resistant organisms (7). Based on the prevalence and characteristics of drug-resistant organisms, at least 95% of patients will receive an adequate regimen (at least two drugs to which their organisms are susceptible) if this four-drug regimen is used at the beginning of therapy (CDC, unpublished data). Even with susceptible organisms, sputum conversion is accomplished more rapidly from positive to negative with a four-drug regimen than with a three-drug regimen of INH, RIF, and PZA (8). DOT is more easily managed with the four-drug regimen since it can be administered intermittently 3 times/week from the beginning of therapy (7). The four-drug regimen also can be administered 2 times/week following a 2-week induction phase of daily therapy (9). Finally, a patient who is treated with the four-drug regimen, but who defaults therapy is more likely to be cured and not relapse when compared with a patient treated for the same length of time with the three-drug regimen.

RECOMMENDATIONS

To avoid the emergence of drug-resistant organisms, the Advisory Council for the Elimination of Tuberculosis (ACET) recommends the following approach to beginning therapy for TB. Susceptibility Testing

All persons with TB from whom M. tuberculosis is isolated should have drugsusceptibility testing performed on their first isolate; these results should be reported promptly to the health-care provider and to the health department.

Such testing will provide the basis for clinical therapeutic decisions. In addition, surveillance of drug-susceptibility reports will help identify emerging drug resistance and help monitor control efforts in areas where resistance is already established. Drug-susceptibility testing also should be performed on additional isolates from patients whose cultures fail to convert to negative within 3 months of beginning therapy, or if there is clinical evidence of failure to respond to therapy. To monitor changes in drug susceptibility patterns in the United States, the "Report of Verified Cases of Tuberculosis" reporting form has been revised to include a section relating to drug susceptibility results from the initial isolate for all reported TB cases. Initial Regimen

The initial treatment of TB should include four drugs. During the first 2 months, the drug regimen should include INH, RIF, PZA, and EMB or SM. When drug susceptibility results are available, the regimen should be altered as appropriate. This regimen should be administered to all patients unless the likelihood of INH or RIF resistance is low. General Principles

Analysis of local rates of drug resistance provides the best basis for determining when the four-drug regimen might not be necessary. Local data may indicate that the population in general is at low risk for drug resistance or that specific and definable subgroups in the population can be defined that are at low risk for drug resistance. In the past, when national INH-resistance rates were about 4% and declining (10), two- and three-drug regimens were considered adequate. Community rates of INH resistance less than 4% may be an indication that an initial regimen with fewer than four drugs may be acceptable. However, continued surveillance of drug susceptibility patterns is necessary to ensure that low rates of drug resistance continue.

Institutions (e.g., health-care and correctional facilities) that are experiencing outbreaks of TB resistant to INH and RIF or that are resuming treatment for a patient with a prior history of anti-TB therapy may need to begin five-drug or six-drug regimens as initial therapy. These regimens should include the four-drug regimen and at least three drugs to which the suspected multidrug-resistant strain may be susceptible.

When the results of drug susceptibility tests become available, regimens should be specifically defined on the basis of those results. For example, patients whose TB organisms are susceptible to INH and RIF should receive a regimen of INH and RIF for a full 6 months, supplemented with PZA during the first 2 months. The treatment regimen of patients with drug-resistant organisms should be determined in consultation with physicians experienced in the treatment of drug-resistant TB.

When results of drug susceptibility tests are not available, either due to a failure to perform the tests or a failure of the test to yield definitive results, the decision to modify therapy should be based on the probability of drug resistance. Where the prevalence of drug resistance is sufficiently substantial to justify starting all patients on the four-drug regimen (i.e., a prevalence of INH resistance greater than or equal to 4%), PZA should be discontinued at 8 weeks, but EMB or SM should be continued (along with INH and RIF) for a total of 6 months. Immunosuppressed Patients

HIV infection and other factors that compromise a patient's immune system are important considerations when clinicians select the most effective regimen for the treatment of TB. These factors are particularly important with drug-resistant TB because of the potential for rapid disease progression and death when patients receive inadequate treatment. Because data from controlled clinical trials are not available to determine if a 6-month regimen is adequate treatment for HIV-infected patients with TB, ACET recommends that such patients be treated for a total of 9 months and for at least 6 months after sputum conversion (11). No evidence suggests that intermittent therapy -- 2 times/week or 3 times/week

  • will not be as effective for the treatment of TB among HIV-infected persons when compared with TB treatment for persons who are not HIV positive.

If drug susceptibility results are not available, EMB or SM should be continued for the entire course of therapy because of the risk of rapid disease progression while the patient is on inadequate therapy. Treatment of Extrapulmonary TB

Regimens that are adequate for treating adults and children with pulmonary TB also should be effective in treating extrapulmonary disease. However, some experts extend the duration of therapy to 9 months for patients with disseminated disease, miliary disease, disease involving the bones or joints, or tuberculous lymphadenitis. The use of adjunctive therapies, such as surgery and corticosteroids, may be beneficial (1). Treatment of Infants and Children

Infants and children with TB should be treated with the same regimens recommended for adults; however, dosage may vary for some drugs (Table 2). Further, EMB is generally not used for children whose visual acuity cannot be monitored (e.g., those less than 6 years of age); SM is an alternative. The inclusion of EMB in the treatment regimen should be considered, however, for all children with organisms resistant to other drugs when susceptibility to EMB has been demonstrated or when susceptibility is likely. Because the risk of dissemination of TB is greater among infants than adults, prompt and vigorous treatment should begin as soon as the diagnosis is suspected. Treatment of TB During Pregnancy

Effective therapy for TB is essential for pregnant women with TB. However, the treatment regimen must be adjusted since SM may cause congenital deafness. SM is the only licensed anti-TB drug documented to have harmful effects on the fetus (1). Routine use of PZA also is not recommended during pregnancy because the risk of teratogenicity has not been determined. In addition, since the 6-month treatment regimen cannot be used and a minimum of 9 months of therapy is recommended, the preferred initial treatment regimen is INH, RIF, and EMB. If resistance to other drugs is likely and susceptibility to PZA also is likely, the use of PZA should be considered and the risks and benefits of the drug carefully weighed. Because the small concentrations of anti-TB drugs in breast milk do not produce toxicity in the nursing newborn, breast feeding should not be discouraged. Further, because these drug levels are so low in breast milk they cannot be relied upon for either prophylaxis or therapy for nursing infants. Directly Observed Therapy (DOT)

A major cause of drug-resistant TB and treatment failure is patient nonadherence to prescribed treatment. Treatment failure and drug-resistant TB can be life-threatening and pose other serious public health risks because they can lead to prolonged infectiousness and increased transmission of TB in the community. DOT is one method of ensuring adherence; it requires that a health-care provider or other designated person observe while the patient ingests anti-TB medications.

DOT should be considered for all patients because of the difficulty in predicting which patients will adhere to a prescribed treatment regimen. Decisions regarding the use of expanded or universal DOT should be based on a quantitative evaluation of local treatment completion rates. If the percentage of patients who complete therapy within 12 months is less than 90% or unknown, the use of DOT should be expanded. If greater than or equal to 90% of patients beginning therapy complete a recommended course of therapy within 12 months, the expanded use of DOT may not be necessary. However, even in these circumstances, consideration should be given to extending the use of DOT to increase the treatment completion rate. All patients with TB caused by organisms resistant to either INH or RIF and all patients receiving intermittent therapy should receive DOT.

DOT programs increase adherence in both rural and urban settings and provide effective treatment for TB (12, 13). A hospital in New York City reported that only 11% of patients under care for TB reported to an outpatient clinic for further treatment when discharged from the hospital (14). In contrast, a program in which DOT is routinely used for all patients had a completion rate of 98% (15).

Although expanding the use of DOT may require additional resources, intermittent, directly observed regimens are cost effective (16) (CDC unpublished data). DOT can be conducted with regimens given once a day, 2 times/week, or 3 times/week.

When TB is initially diagnosed, medical providers should explain to the patient about the disease, treatment, and the importance of completing the recommended course of therapy. Medical providers should also verify that the patient understands this information. When DOT is administered, the method must be specifically defined for each patient and be based on a thorough assessment of each patient's needs, living/employment conditions, and preferences. The patient and the provider should agree on a method that ensures the best possible DOT routine and maintains confidentiality. Patients who receive daily therapy can be successfully managed with self-administered therapy. Public health officials responsible for TB treatment should be notified when patients not receiving DOT miss appointments or demonstrate other nonadherent behaviors. These patients should be placed on DOT, and all regimens administered 2 times/week or 3 times/week should be administered as DOT for the duration of therapy.

Effective use of DOT sometimes requires an outreach worker to go into the community to locate a patient and administer each dose of medication. However, most patients can receive the daily, 2 times/week, or 3 times/ week treatment at a location agreed on by both the provider and the patient. DOT can be arranged and administered in various settings, including TB clinics, community health centers, migrant clinics, homeless shelters, prisons or jails, nursing homes, schools, drug treatment centers, hospitals, HIV/AIDS clinics or hostels, or occupational health clinics.

In some situations, another responsible person other than a health-care worker may administer DOT. Persons administering DOT may include physicians, nurses, health care aides, nursing home staff, correctional facility personnel, staff of community-based organizations, school nurses or teachers, reliable volunteers, drug treatment center employees, social and welfare caseworkers, and clergy or other community leaders. These arrangements require careful supervision by the medical provider. The use of incentives or enablers (e.g., providing transportation or car/bus fare to the DOT site) may promote patient adherence to a DOT program. The use of combined preparations of INH and RIF (e.g., Rifamate Registered) or INH, RIF, and PZA (not available in the United States) may also improve patient adherence.

Poor patient adherence is a multifaceted problem; additional research is needed to clarify the role of operational, environmental, behavioral, and other factors in determining adherence. A research agenda is described in "Problem 38" of the National Action Plan to Combat Multidrug-Resistant Tuberculosis (17).

CONCLUSION

These recommendations update previous CDC/American Thoracic Society (ATS) recommendations for the treatment of TB among adults and children (1). The ATS Statements Committee is revising that previous report with representatives from CDC, the American Academy of Pediatrics, and the Infectious Disease Society of America and may offer similar recommendations. Questions concerning these recommendations should be made to: CDC, National Center for Prevention Services, Division of TB Elimination, Clinical Research Branch, 1600 Clifton Road, MS E-10, Atlanta, GA 30333, (404) 639-2530.

References

  1. American Thoracic Society, CDC. Treatment of TB and TB infection in adults and children. Am Rev Respir Dis 1986;134:355- 63.
  2. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328(8):521.
  3. CDC. Nosocomial transmission of multidrug-resistant TB to health-care workers and HIV- infected patients in an urban hospital -- Florida. MMWR 1990;39:718.
  4. CDC. Nosocomial transmission of multidrug-resistant TB among HIV-infected persons -- Florida and New York, 1988-1991. MMWR 1991;40(34):585.
  5. CDC. Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system -- New York. MMWR 1991;41:507.
  6. Snider DE, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of TB cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;132:125.
  7. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen given for 6 months for pulmonary TB. Second report: the results of final results up to 24-months. Tubercle 1982;63:89.
  8. Combs DL, O'Brien RJ, Geiter LJ. USPHS TB short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397.
  9. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose 6-month therapy for pulmonary and extrapulmonary TB. A twice-weekly, directly observed, and cost effective regimen. Ann Int Med 1990;112(6):407.
  10. CDC. Primary resistance to anti-TB drugs -- United States. MMWR 1983;32(40):521.
  11. CDC. TB and human immunodeficiency virus infection: recommendations of the advisory committee for the elimination of TB (ACET). MMWR 1989;38(17):236,243.
  12. Sbarbaro JA, Johnson S. TB chemotherapy for recalcitrant outpatients administered twice-weekly. Am Rev Respir Dis 1968;97:895.
  13. Mcdonald RJ, Memon AM, Reichman LB. Successful supervised ambulatory management of TB treatment failures. Ann Intern Med 1982;96:297.
  14. Brudney K, Dobkin J. Resurgent TB in New York City. Human immunodeficiency virus, homelessness and the decline of TB programs. Am Rev Respir Dis 1991;144:745.
  15. CDC. Improving adherence to antituberculosis therapy -- South Carolina and New York. MMWR 1993;42(4):74.
  16. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis -- we can't afford not to try it. N Engl J Med 1993;328(8):576.


Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #